Cancer Prevention with Aspirin for Patients with Lynch Syndrome

Long-term follow-up data show that daily aspirin may significantly reduce colorectal cancer risk for Lynch syndrome patients.

Data consistently show a potential colorectal cancer (CRC) preventive benefit for aspirin use in the general population. Prior results from the CAPP2 trial previously demonstrated a potential reduction in the risk for Lynch-related CRC and non-CRC cancers with aspirin use at a mean follow-up of 4.6 years (Lancet 2011; 378:2081). Investigators have now updated results of the CAPP2 trial with all patients at or beyond 10 years of follow-up.

In this industry-funded, international, randomized, controlled trial, 861 patients with Lynch syndrome were randomized to receive aspirin (600 mg daily) or placebo for at least 2 years. Most patients were female (55%), most had a genetic diagnosis of Lynch syndrome (84%), and the median time on aspirin inte…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Cancer Prevention with Aspirin for Patients with Lynch Syndrome

Topics

Reviewing Author